Anticoagulants, Antiplatelets, and Thrombolytics

1. Front Matter

   Pages i-xi

   PDF

2. In Vitro Methods of Evaluating Antithrombotics and Thrombolytics

   • Shaker A. Mousa

   Pages 1-28

3. In Vivo Models for the Evaluation of Antithrombotics and Thrombolytics

   • Shaker A. Mousa

   Pages 29-107

4. Heparin and Low-Molecular Weight Heparins in Thrombosis and Beyond

   • Shaker A. Mousa

   Pages 109-132

5. Laboratory Methods and Management of Patients with Heparin-Induced Thrombocytopenia

   • Margaret Prechel, Walter P. Jeske, Jeanine M. Walenga

   Pages 133-156

6. Novel Anticoagulant Therapy: Principle and Practice

   • Shaker A. Mousa

   Pages 157-179

7. Oral Direct Factor Xa Inhibitors, with Special Emphasis on Rivaroxaban

   • Shaker A. Mousa

   Pages 181-201

8. Antiplatelet Therapies: Drug Interactions in the Management of Vascular Disorders

   • Shaker A. Mousa

   Pages 203-219

9. Prasugrel: A Novel Platelet ADP P2Y12 Receptor Antagonist

   • Shaker A. Mousa, Walter P. Jeske, Jawed Fareed

   Pages 221-228

10. Antithrombotic Effects of Naturally Derived Products on Coagulation and Platelet Function

    • Shaker A. Mousa

    Pages 229-240

11. Assessment of Anti-Metastatic Effects of Anticoagulant and Antiplatelet Agents Using Animal Models of Experimental Lung Metastasis

    • Ali Amirkhosravi, Shaker A. Mousa, Mildred Amaya, Todd Meyer, Monica Davila, Theresa Robson et al.

    Pages 241-259

12. Adhesion Molecules: Potential Therapeutic and Diagnostic Implications

    • Shaker A. Mousa

    Pages 261-276

13. Pharmacogenomics in Thrombosis

    • Shaker A. Mousa

    Pages 277-289

14. Diagnosis and Management of Sickle Cell Disorders

    • Shaker A. Mousa, Mohamad H. Qari

    Pages 291-307

15. Back Matter

    Pages 309-316

    PDF

During the past decade, remarkable progress has been made in the development of newer drugs to prevent and treat thromboembolic disorders, such as oral direct anti-Xa and anti-IIa antagonists, as well as oral antiplatelet ADP antagonists with rapid onset and offset. In addition, there has been concentrated effort aimed at identifying novel uses of traditional antithrombotic drugs, such as aspirin, heparin, and oral anticoagulants, as well as combinations of agents, such as more than one antiplatelet, antiplatelet with anticoagulant, antiplatelet with or without thrombolytic. Anticoagulants, Antiplatelets, and Thrombolytics, Second Edition provides updates on various strategies in thrombosis, experimental models, and clinical and recent advances in the discovery and development of novel antithrombotics. As a volume in the highly successful Methods in Molecular Biology™ series, this collection provides the kind of detailed description and implementation advice that is crucial for getting optimal results. Easy to use and up to date, Anticoagulants, Antiplatelets, and Thrombolytics, Second Edition is an ideal guide for researchers aiming for the future of this vital field, focusing on the prevention of thromboembolic disorders and the protection of the vascular endothelium.

• Anti-Xa agents
• Antithrombotic drugs
• Oral anticoagulants
• Pharmaceutical development
• Thromboembolic disorders
• Vascular endothelium
• endothelium

From the reviews of the second edition:

“Text thoroughly presented the subject of antithrombotic and anticoagulant therapy in great depth and with complete review of the subject. In 13 chapters outstanding experts in their field have provided the cardiovascular specialist, hematologist, and pathologist with a thorough updating of the pharmacology of antithrombotic and anticoagulant therapy. … text should provide anyone working in the field of cardiovascular medicine or surgery and in hematology or pathology with a way to keep current with developments in the field of cardiovascular pharmacology. We recommend it highly.” (Harry L. Messmore and William H. Wehrmacher, Clinical and Applied Thrombosis/Hemostasis, November, 2010)

“Recent advances in testing and use of anticoagulants, antiplatelets, and thrombolytics and the essentials of efficacy testing, novel direct thrombin inhibitors, use of naturally-derived products, and pharmacogenomics in thrombosis. … The book is likely to be of interest to both academic scientists and practitioners interested in the treatment of patients with thrombosis. … This is very likely to make it onto the shelf in our laboratory, in particular as a reference for current advances in antithrombotics and thrombolytics.” (James P. Luyendyk, Doody’s Review Service, December, 2010)

• , Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sc, Rensselaer, USA

  Shaker A. Mousa

Policies and ethics